NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Suzhou NeuPharma Co., Ltd.

Suzhou NeuPharma Co., Ltd.

Private
SuzhouHealthcare & Life Scienceshttps://neupharma.com/

Last Round

Series B

Extension

Dec 14, 2018

Company Overview

Suzhou NeuPharma Co., Ltd. is a biopharmaceutical company that engages in the research and development of innovative medicines for unmet medical needs, with a focus on anti-cancer therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

small molecule drugstargeted cancer therapyoncology pipelineclinical stage biotechdrug discoveryprecision oncologyEGFR inhibitorBRAF inhibitornon-small cell lung cancerNSCLCdrug licensingcancer drug resistancesolid tumor therapyNa+/K+-ATPase inhibitor

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Suzhou NeuPharma Co., Ltd. Comparables

Compare Suzhou NeuPharma Co., Ltd. with similar companies based on industry and business-model similarity.

Suzhou NeuPharma Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ABM Therapeutics
81%
Shanghai Henlius Biotech Inc
78%
Innovent Biologics
77%

Suzhou NeuPharma Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionDec 14, 2018
Series BJun 28, 2018

Suzhou NeuPharma Co., Ltd. Investors

Notable investors and investment history

Suzhou NeuPharma Co., Ltd. investors
InvestorRounds
China Science and Technology Industry Investment ManagementSeries B Extension
Longwater InvestmentSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 8, 2024

    Monthly visitors increased 252% MoM.

Suzhou NeuPharma Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Suzhou NeuPharma Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Suzhou NeuPharma Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSuzhou
Employee Range1
Year Founded2009
Last FundingDec 14, 2018

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.